Cumberland pharmaceuticals reports 2.4m patient doses delivered, no product recalls, no fda issues in 2021

The company's annual sustainability report highlights its continued focus on and commitment to environmental, social and governance issues nashville, tenn. , aug. 8, 2022 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company, today released its 2021 sustainability report detailing its activities regarding its involvement in environmental, social and governance matters.
CPIX Ratings Summary
CPIX Quant Ranking